Watts, Gerald F.

Statin therapy and plasma coenzyme Q10 concentrations—A systematic review and meta-analysis of placebo-controlled trials

Banach, M., Serban, C., Ursoniu, S., Rysz, J., Muntner, P., Toth, P. P., Jones, S. R., Rizzo, M., Glasser, S. P., Watts, G. F., et al. (2015) · Pharmacological Research

Coenzyme Q10 studies and effectsLipoproteins and Cardiovascular Health

Cited by 195

Optimizing cholesterol treatment in patients with muscle complaints

Rosenson, R. S., Baker, S., Banach, M., Borow, K. M., Braun, L. T., Bruckert, E., Brunham, L. R., Catapano, A. L., Elam, M. B., Mancini, G. B. J., et al. (2017) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 193

Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up

Vallejo-Vaz, A. J., Robertson, M., Catapano, A. L., Watts, G. F., Kastelein, J. J., Packard, C. J., Ford, I., & Ray, K. K. (2017) · Circulation

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 185

Randomized controlled trial of the effect of n–3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity

Chan, D. C., Watts, G. F., Mori, T. A., Barrett, P. H. R., Redgrave, T. G., & Beilin, L. J. (2003) · The American Journal of Clinical Nutrition

Fatty Acid Research and HealthLipid metabolism and disorders

Cited by 185

Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk

Watts, G. F., Rosenson, R. S., Hegele, R. A., Goldberg, I. J., Gallo, A., Mertens, A., Baass, A., Zhou, R., Muhsin, M., Hellawell, J., et al. (2025) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 178

Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia

Gaudet, D., Pall, D., Watts, G. F., Nicholls, S. J., Rosenson, R. S., Modesto, K., San Martin, J., Hellawell, J., & Ballantyne, C. M. (2024) · JAMA Cardiology

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 172

Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia

Chan, D. C., Watts, G. F., Barrett, P. H. R., Beilin, L. J., Redgrave, T. G., & Mori, T. A. (2002) · Diabetes

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 160

Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome

Cussons, A. J., Watts, G. F., Burke, V., Shaw, J. E., Zimmet, P. Z., & Stuckey, B. G. A. (2008) · Human Reproduction

Ovarian function and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 140

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 140

Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity

Chan, D. C., Watts, G. F., Barrett, P. H., Mamo, J. C., & Redgrave, T. G. (2002) · Clinical Chemistry

Lipid metabolism and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 117

Demystifying the management of hypertriglyceridaemia

Watts, G. F., Ooi, E. M. M., & Chan, D. C. (2013) · Nature Reviews Cardiology

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 115

Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin‐associated muscle symptoms, under blinded and open‐label conditions

Penson, P. E., Mancini, G. B. J., Toth, P. P., Martin, S. S., Watts, G. F., Sahebkar, A., Mikhailidis, D. P., Banach, M., & on behalf of Lipid and Blood Pressure Meta‐Analysis Collaboration (LBPMC) Group & International Lipid Expert Panel (ILEP) (2018) · Journal of Cachexia, Sarcopenia and Muscle

Pain Management and Placebo EffectLipoproteins and Cardiovascular Health

Cited by 110

Identification of lipoproteins of intestinal origin in human atherosclerotic plaque

Pal, S., Semorine, K., Watts, G. F., & Mamo, J. (2003) · Clinical Chemistry and Laboratory Medicine

Cholesterol and Lipid MetabolismLipoproteins and Cardiovascular Health

Cited by 107

RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts

Watts, G. F., Schwabe, C., Scott, R., Gladding, P. A., Sullivan, D., Baker, J., Clifton, P., Hamilton, J., Given, B., Melquist, S., et al. (2023) · Nature Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 105

Triglycerides and atherogenic dyslipidaemia: Extending treatment beyond statins in the high-risk cardiovascular patient

Watts, G. F., & Karpe, F. (2011) · Heart

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 97

An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?

Chan, D. C., Chen, M. M., Ooi, E. M. M., & Watts, G. F. (2008) · International Journal of Clinical Practice

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 85

Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity: Multicenter Tracer Kinetic Study

Borén, J., Watts, G. F., Adiels, M., Söderlund, S., Chan, D. C., Hakkarainen, A., Lundbom, J., Lundbom, N., Matikainen, N., Kahri, J., et al. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipid metabolism and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 72

RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia

Gaudet, D., Clifton, P., Sullivan, D., Baker, J., Schwabe, C., Thackwray, S., Scott, R., Hamilton, J., Given, B., Melquist, S., et al. (2023) · NEJM Evidence

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 71

Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics.

Chan, D. C., Watts, G. F., Nguyen, M. N., & Barrett, P. H. R. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 70

Dyslipidaemia in the metabolic syndrome and type 2 diabetes: Pathogenesis, priorities, pharmacotherapies

Chan, D. C., & Watts, G. F. (2011) · Expert Opinion on Pharmacotherapy

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 69

An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia

Grundy, S. M., Arai, H., Barter, P., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A., Davidson, M. H., Genest, J., Kesäniemi, Y. A., et al. (2014) · Atherosclerosis

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 68

Postprandial hypertriglyceridaemia revisited in the era of non-fasting lipid profile testing: a 2019 Expert Panel Statement, Main Text

Kolovou, G. D., Watts, G. F., Mikhailidis, D. P., Pérez-Martínez, P., Mora, S., Bilianou, H., Panotopoulos, G., Katsiki, N., Ooi, T. C., Lopez-Miranda, J., et al. (2019) · Current Vascular Pharmacology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 61

Effect of weight loss on postprandial lipemia and low-density lipoprotein receptor binding in overweight men

James, A. P., Watts, G. F., Barrett, P. H. R., Smith, D., Pal, S., Chan, D. C., & Mamo, J. C. L. (2003) · Metabolism

Lipid metabolism and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 54

Docosahexaenoic Acid But Not Eicosapentaenoic Acid Increases LDL Particle Size in Treated Hypertensive Type 2 Diabetic Patients

Woodman, R. J., Mori, T. A., Burke, V., Puddey, I. B., Watts, G. F., Best, J. D., & Beilin, L. J. (2003) · Diabetes Care

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 48